- Previous Close
8.10 - Open
8.26 - Bid --
- Ask --
- Day's Range
7.72 - 8.40 - 52 Week Range
3.79 - 17.60 - Volume
48,833 - Avg. Volume
19,329 - Market Cap (intraday)
291.184M - Beta (5Y Monthly) 0.55
- PE Ratio (TTM)
-- - EPS (TTM)
-1.73 - Earnings Date Mar 13, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
12.90
Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company's lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah S.A. was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.
www.nyxoah.comRecent News: NYXH.BR
View MorePerformance Overview: NYXH.BR
Trailing total returns as of 12/27/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: NYXH.BR
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: NYXH.BR
View MoreValuation Measures
Market Cap
303.16M
Enterprise Value
255.51M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
48.81
Price/Book (mrq)
2.90
Enterprise Value/Revenue
50.28
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-23.14%
Return on Equity (ttm)
-49.69%
Revenue (ttm)
5.08M
Net Income Avi to Common (ttm)
-52.98M
Diluted EPS (ttm)
-1.73
Balance Sheet and Cash Flow
Total Cash (mrq)
70.98M
Total Debt/Equity (mrq)
22.28%
Levered Free Cash Flow (ttm)
-35.99M